Global Programme to Eliminate Lymphatic Filariasis: The Processes Underlying Programme Success
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Global Programme to Eliminate Lymphatic Filariasis: The Processes Underlying Programme Success

Filetype[PDF-1.01 MB]


  • English
    • Details Supporting Files You May Also Like

    Details:

    • Alternative Title:
      PLoS Negl Trop Dis
    • Personal Author:
    • Description:
      Lymphatic filariasis (LF) is caused by filarial worms that live in the lymphatic system and commonly lead to lymphoe- dema, elephantiasis, and hydrocele. LF is recognized as endemic in 73 countries and territories; an estimated 1.39 billion (thou- sand million) people live in areas where filariasis has been endemic and is now targeted for treatment [1]. Global mo- mentum to eliminate LF has developed over the past 15 years as a result not only of research demonstrating the value of single-dose treatment strategies and point- of-care diagnostic tools, but also of both the generous donations of medicines from the following committed pharmaceutical companies: GlaxoSmithKline (albenda- zole), Merck (ivermectin), and Eisai (di- ethylcarbamazine; DEC), and the essential financial support for programme imple- mentation from the donor community [2]. During 2011, more than 50 countries carried out LF elimination programmes, and more than 500 million people re- ceived mass treatment [1]. A principal reason for the programme’s dramatic expansion and success to date has been the galvanizing of efforts of all key partners around a common policy framework created and coordinated through the World Health Organization’s Global Pro gramme to Eliminate Lymphatic Filariasis (GPELF). This report, rather than high- lighting the very considerable contribu- tions of each individual partner or even chronicling most of the specific achieve- ments of the GPELF, instead focuses on the details of the underlying processes themselves and their importance in deter- mining programme success.
    • Subjects:
    • Source:
      PLoS Negl Trop Dis. 2014; 8(12).
    • Document Type:
      Journal Article
    • Collection(s):
    • Main Document Checksum:
    • Download URL:
    • File Type:

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov